Results 131 to 140 of about 58,972 (283)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease

, 2018
Satohiro Matsumoto, Hirosato Mashima Department of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Japan Abstract: Anti-TNFα drugs have been shown to be effective for maintaining stable remission in patients with Crohn ...
Matsumoto S, Mashima H
core  

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

, 2010
Reasons for infliximab failure in Crohn's disease and ulcerative colitis are debated. Serum levels of infliximab and anti-infliximab antibodies have been associated with loss of response.
Mark Andrew Ainsworth, Bendtzen, Klaus, Jørn Brynskov, Casper Steenholdt, Brynskov, Jørn, Thomsen, Ole Østergaard, Klaus Bendtzen, Steenholdt, Casper, Ainsworth, Mark Andrew, Ole Østergaard Thomsen   +9 more
core   +1 more source

Plasma Cell Mucositis: A 20‐Year Retrospective Review at a Tertiary Center

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes.
Miguel A. Aristizabal‐Torres, Jessi M. Larrinaga, Katherine Bodiford, Olayemi Sokumbi, Leila Tolaymat   +4 more
wiley   +1 more source

Cochlear Implantation in Autoimmune Inner‐Ear Disease: Outcome and Patient‐Reported Benefit

The Laryngoscope, EarlyView.
This study demonstrates that patients with secondary autoimmune inner‐ear disease (AIED) achieve significant improvements in speech perception and quality of life following cochlear implantation. Although AIED patients may show slightly lower performance in noisy environments compared to controls, their subjective hearing benefit converges with matched
Merete Hartmann, David Oestreicher, Marc Albert Hüser, Dirk Beutner, Christian Wrobel   +4 more
wiley   +1 more source

Infliximab therapy for moderately severe Crohn’s disease and ulcerative colitis: a retrospective comparison over 6 years

, 2011
Raed Alzafiri1, Christina A Holcroft2, Paula Malolepszy1, Albert Cohen1, Andrew Szilagyi11Jewish General Hospital, Division of Gastroenterology, Department of Medicine, McGill University School of Medicine, Montreal, Quebec, Canada; 2Centre for Clinical ...
Paula Malolepszy, et al, Christina A Holcroft, Raed Alzafiri   +3 more
core  

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

Single‐center experience of the Crohn's disease exclusion diet in the United States: A retrospective study

Nutrition in Clinical Practice, EarlyView.
Abstract Background The Crohn's Disease Exclusion Diet (CDED) offers a dietary means of inducing and maintaining remission for patients with Crohn's disease (CD). Descriptions of efficacy have emerged primarily from Israel, Europe, and Canada. Here, we offer real‐world experience, from a tertiary care center in the United States. Methods We conducted a
Mayah Greenfield, Caroline Salozzo, Wenya Chen, Jennifer Strople, Jeffrey Brown, Joseph Runde   +5 more
wiley   +1 more source

Prediction of deep remission through serum TNF-α level at 1 year of treatment in pediatric Crohn’s disease

Scientific Reports
A pilot study investigated the cytokine profile (IL-6, TNF-α, IL-17 A, and IL-10) at diagnosis, affecting infliximab (IFX) trough levels (TLs) in pediatric patients with Crohn’s disease (CD).
Seon Young Kim, Yiyoung Kwon, Eun Sil Kim, Yoon Zi Kim, Hansol Kim, Yon Ho Choe, Mi Jin Kim   +6 more
doaj   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Comparison of efficacy of the tumour necrosis factor alpha blocking agents Etanercept and Infliximab in patients with active rheumatoid arthritis

, 2005
Background: Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved the outcomes in patients with rheumatoid arthritis (RA).
SANGARI D, DE FILIPPIS LG, MICALI G, ROMEO C, SCIBILIA G, BAGNATO, Gianfilippo, CALIRI A, LO GULLO R., BARTOLONE S   +8 more
core